AMGN vs CDNA: fair value comparison
Amgen Inc. and CareDx, Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, AMGN currently sits closer to the top of our discount ranking. CDNA carries the stronger quality grade.
| AMGN | CDNA | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $432.42 | $47.85 |
| 12-month range | $286.92–$385.70 | $13.85–$47.85 |
| Sector rank | #104 of 113 Healthcare | #107 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | C | — |
| Leverage | High | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: AMGN fair value analysis · CDNA fair value analysis